DYRK1A and Dravet syndrome: The present review extends those recent analyses by emphasizing an additional but crucial aspect of the therapeutic potential of Dyrk1a inhbition for DS – the importance of understanding when and where Dyrk1a expression and activity is elevated and determining whether some periods of elevated Dyrk1a may represent sensitive periods of developmental vulnerability for establishing long‐lasting DS structural and functional phenotypes.